| Authors: |
Spronk DB; Trimbos Institute, Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands, dspronk@trimbos.nl., van Beek RJJ; Trimbos Institute, Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands., Smits RLA; Trimbos Institute, Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands., Andree R; Trimbos Institute, Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands., den Hollander W; Trimbos Institute, Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands., Freeman TP; Clinical Psychopharmacology Unit, University College London, London, UK.; Addiction and Mental Health Group, Department of Psychology, University of Bath, Bath, UK., Curran HV; Clinical Psychopharmacology Unit, University College London, London, UK., Waldron J; Clinical Psychopharmacology Unit, University College London, London, UK., Grabski M; Clinical Psychopharmacology Unit, University College London, London, UK., Blankers M; Trimbos Institute, Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands.; Arkin Mental Health Care, Department of Research, Amsterdam, The Netherlands., van Laar MW; Trimbos Institute, Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands. |
